Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: The University Of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Fecal Microbiota Transplant National Registry
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Tissue Sample Collection from Patients with Head and Neck Cancer and from Healthy Participants
Recruiting
RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing tissue samples from patients with head and neck cancer and from healthy participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/26/2025
Locations: Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee
Conditions: Head and Neck Cancer
Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
Recruiting
This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia. Further, we will add an exploratory outcome to evaluate the neonatal body composition and anthropometric data to better understand neonatal impacts of maternal metabolic dysfunction.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/24/2025
Locations: University of Tennessee Medical Center, Knoxville, Tennessee
Conditions: Preeclampsia, Preeclampsia (PE), Preeclampsia (PE) Risk, Obesity and Obesity-related Medical Conditions, Pregnancy, Pregnancy Complications, Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy, Gestational Complications
Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study
Recruiting
Minimal information is available regarding changes in whole-body metabolism in ovarian cancer patients, and no study has assessed whole-body lipid metabolism in this patient population. In this pilot study we will assess fasting and postprandial lipid metabolism of ovarian cancer patients before, during, and after treatment via indirect calorimetry.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Tennessee Graduate School of Medicine, Knoxville, Tennessee
Conditions: Ovary Cancer
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Recruiting
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) dise... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Urology Associates, P.C., Nashville, Tennessee
Conditions: Metastatic Castration-Resistant Prostate Cancer
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: West Tennessee Research Institute, Jackson, Tennessee
Conditions: Lupus Erythematosus, Systemic
Retrieval Practice for Word Learning for Deaf and Hard of Hearing Children
Recruiting
This study is designed to advance the promising yet underutilized research on retrieval practice by evaluating the effectiveness and efficiency of two key retrieval practice features (feedback and spacing). The study uses four single case adapted alternating treatments studies, each with four 5- to 8-year-old children who are deaf and hard of hearing to evaluate the effects of feedback and spacing on the efficiency of word learning and retention.
Gender:
ALL
Ages:
Between 5 years and 8 years
Trial Updated:
01/22/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Hearing Loss, Language Impairment
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: West Cancer Center, Germantown, Tennessee
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Memphis, Tennessee
Conditions: Binge-Eating Disorder
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Recruiting
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Memphis, Tennessee
Conditions: Major Depressive Disorder
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Recruiting
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
01/21/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma